Back Back
ELCC 2025 Updates
Key Updates in Non-Small-Cell Lung Cancers From the ELCC 2025 Annual Meeting

Released: April 29, 2025

Expiration: October 28, 2025

David Planchard
David Planchard, MD, PhD
Activity Information

Activity

Progress
1
Course Completed
Continue

The European Lung Cancer Congress (ELCC) 2025 Annual Meeting featured updated data for several significant studies in advanced non-small-cell lung cancer (NSCLC). In this commentary, David Planchard, MD, PhD highlights what he considers the most important presentations, which we are covering as a part of CCO’s Independent Conference Coverage of ELCC 2025.

Top Presentations in Advanced NSCLC

  • Final overall survival (OS) of the phase III MARIPOSA trial (abstract 4O): Median OS of first-line amivantamab plus lazertinib was significantly improved vs osimertinib in patients with EGFR-mutated (Ex19del or L858R) advanced NSCLC. OS benefit with the combination regimen is anticipated to be more than 12 months and demonstrates that amivantamab with lazertinib may be a new standard of care in the first-line setting.
  • Primary efficacy analysis of the phase II SAVANNAH trial (abstract 2O): Patients with EGFR-mutated MET-overexpressed or -amplified, advanced NSCLC with progression on first-line osimertinib had durable responses to the combination of savolitinib and osimertinib. The ongoing phase III SAFFRON trial could support savolitinib plus osimertinib as a new therapeutic option for these patients.
  • SOHO-01 study expansion cohorts (abstract 3O): BAY 2927088, a reversible HER2 tyrosine kinase inhibitor, was tested in a phase I/II trial for patients with advanced NSCLC, HER2-activating mutations, and disease progression after prior systemic therapy. This agent resulted in durable responses for patients without prior HER2-targeted treatments and for patients previously treated with HER2-targeted antibody–drug conjugates, and is currently being tested in the first-line setting in the phase III SOHO-02 trial.
  • Results from the ORCHARD study (abstract 1O): This biomarker-directed, phase II study tested multiple different combination regimens in patients with advanced EGFR-mutated NSCLC who progressed on first-line osimertinib. The current analysis reported results of the combination of osimertinib plus datopotamab deruxtecan (Dato-DXd) 4 mg/kg vs osimertinib plus Dato-DXd 6 mg/kg. Encouraging progression-free survival (PFS) and overall response rate data suggest the combination of osimertinib with 6 mg/kg Dato-DXd is efficacious with manageable safety in this setting.
  • Phase III LAURA trial updated OS results (abstract LBA4): Primary analysis of the LAURA study showed that osimertinib significantly improved PFS vs placebo for patients with locally advanced, unresectable, EGFR-mutated (Ex19del or L858R), stage III NSCLC and led to FDA and EMA approval of osimertinib for this patient population without progression during or following definitive platinum-based chemoradiation therapy. The updated analysis continues to show a trend toward OS benefit and postprogression outcomes benefit including time to first or second treatments for osimertinib vs placebo, confirming osimertinib as the latest standard of care in this setting.

Additional Studies of Interest

  • EMPOWER-Lung 1 exploratory analysis (abstract 16P): This phase III study randomized patients with previously untreated advanced NSCLC with PD-L1 ≥50% and no EGFR, ALK, or ROS1 mutations to cemiplimab monotherapy or 4 to 6 cycles of chemotherapy. Patients who progressed on first-line cemiplimab could then continue treatment plus 4 cycles of chemotherapy. 5-year follow-up data show positive PFS and OS results for this cemiplimab treatment strategy, which investigators conclude could avoid early chemotherapy without negatively affecting outcomes compared to using chemotherapy in the first line.

Remember to Check the CCO Website for More ELCC 2025 Coverage!
Check the CCO website to find the downloadable slidesets summarizing these key studies and a comprehensive analysis by the expert faculty exploring the clinical implications of these data in a CME-certified text-based module.

Continue

Poll

1.

Which of the following therapeutic strategies are you using in your current clinical practice?

Submit